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Introduction 
In 1922, Evans and Bishops published the first article about the discovery of vitamin E, which 
is crucial for the normal physiological functions. In the nature, vitamin E exists as a mixture 
of eight forms such as α-, β-, γ-, δ-tocopherols, and tocotrienols. However, the activity of 
these analogues is quite various, it seems that α-tocopherol is the most effective against the 
vitamin E deficiency disease and it can reach the highest plasma concentration in the human 
body. 
The mechanism of action of vitamin E is extremely complex. On the one hand, as an 
antioxidant, α-tocopherol can protect against oxidative damage in membranes and 
lipoproteins by way of scavenging of reactive oxygen and nitrogen species and inhibiting of 
lipid peroxidation. Moreover, beyond of the protection, tocopherol participates in the action of 
redox regulated enzymes and transcriptions factors. On the other hand, α-tocopherol also has 
a non-antioxidant molecular mechanism of action. Many studies report that α-tocopherol 
binds non-covalently to several proteins and affects their efficacy.  
Vitamin E plays a significant role in pregnancy, the enhanced plasma level of α-tocopherol 
protects foetus, placenta and uterus from oxidative damage. It is also known, that vitamin E 
possesses an anti-inflammatory ability thus, in the last decade it has been suggested that 
vitamin E may help the treatment or prevention of asthma.  
In the arachidonic acid cascade, the phospholipids of cell membrane transform to different 
types prostanoids such as thromboxane, prostacyclin and prostaglandin. Several enzymes 
catalyse this conversion, however COX is amongst the most important. During the 
transformation, due to peroxidase activity of COXs, reactive oxygen species (ROS) can be 
released. 
The liberated PGs play an important role in contraction or relaxation of smooth muscles and 
cervical ripening during pregnancy.  
Many of the COX inhibitors are applied as non-steroidal anti-inflammatory drugs (NSAIDs). 
The NSAIDs are one of the most frequently used medicines in the world. COX inhibitors 
relax smooth muscles via diminish the production and release of prostaglandins. Thus, in 
clinical practise they are used for preterm therapy till 35 weeks of pregnancy. So far, only a 
few studies are published about the association of vitamin E and COXs, in addition their 
results are inconsistent. 
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Aims 
The mechanism of action of vitamin E is still not fully understood. In addition, based on 
literature data we hypothesized that it may be able to alter the COXs activity. Thus, the focus 
of my PhD thesis was to determine how α-tocopherol succinate modifies the effects of COX-
inhibitors on several types of smooth muscles and cervical ripening. Accordingly, the 
following aims were set:  
 
1. Since, prostaglandins liberated by COX enzymes have a crucial role in development of 
uteri and tracheal smooth muscle contraction, the first purpose of our study was to 
investigate the effects of non-selective COX inhibitor diclofenac, selective COX-2 
inhibitor rofecoxib and selective COX-1 inhibitor SC-560 alone and after pre-
treatment of tocopherol in non-pregnant, 22-day-pregnant rat uteri and trachea tissues 
in vitro. 
2. Prostaglandins also participate in cervical ripening process. Hence, the second aim of 
this study was to examine the action of tocopherol and mentioned COX inhibitors on 
non-pregnant and 22-day-pregnant rat cervical resistance in vitro. 
3. The third aim of this study was to analyse how the tocopherol alters the activity of 
COX-1 and 2 in uteri, cervical and tracheal tissues. 
4. As we hypothesized that tocopherol may modify the effects of COX inhibitors via 
modification of COX enzymes activity, the fourth aim was to observe how  tocopherol 
and COX inhibitors alone and in combination change the time of the initiation of 
parturition in rats in vivo. 
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Materials and methods 
All experiments involving animal subjects were carried out with the approval of the 
Hungarian Ethical Committee for Animal Research (permission number: IV/198/2013).  
Mature female (180-200 g) and male (240-260 g) Sprague-Dawley rats were mated in a 
special mating cage. Vaginal smears sample were taken from the female rats and a sperm 
search was performed under a microscope at a magnification of 1200x. If there was 
copulation plug or the vaginal smears were positive the female rats were separated as first-day 
pregnant animals.  
In vitro studies 
22-day-pregnant and non-pregnant rats in oestrous phase were used for in vitro studies. 
Before preparation of uteri, trachea and cervix, animals were terminated by CO2 inhalation. 
Moreover, in any cases the organ bath was heated at 37 °C and carbogen (95% O2 + 5% 
CO2) was bubbled into the chambers. The tension of cervix, the contraction of uterus and the 
tone of trachea were measured and recorded with a SPEL Advanced ISOSYS Data 
Acquisition System (MDE Ltd., Budapest, Hungary). Tissues were incubated for 1 h with a 
buffer renewal in every 15 minutes. Then samples were equilibrated for another 60 min with 
α-tocopherol succinate (10−7 M); it was added to samples after every wash of buffer solution. 
The control preparations were incubated for 1 h without tocopherol. 
Preparation of uteri 
After the termination, uterus samples were cut into 5-mm long muscle rings, were mounted 
vertically in an organ baths containing 10 ml de Jong buffer and their initial tension was set to 
1.5 g. After the incubation period, the control contractions of uteri were evoked with 25mM 
KCl and the cumulative dose-response curves of non-selective COXi diclofenac (10− 9–10−5 
M) and COX-2 selective inhibitor rofecoxib (10− 10–10− 5 M) were obtained.  
Preparation of trachea 
Tracheas were dissected from non-pregnant rats. The tracheal tube was sliced into 4-5 mm 
wide rings and then was placed in Krebs buffer. After the tracheal samples were installed with 
their longitudinal axis vertically by hooks, their initial strains were set to about 2.00 g. The 
tracheal tone reducing effect of non-selective COXi diclofenac (10− 9–10−5 M) and COX-2 
selective inhibitor rofecoxib (10− 10–10− 5 M) were obtained. 
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Preparation of cervix 
The cervices were separated from the two horns of 22-day-pregnant and non-pregnant uterus, 
then their two rings were cut with razorblade. The samples were mounted vertically by hooks 
in an organ bath containing de Jong solution to setting the initial tension 1.00 g, cervices were 
equilibrated with mentioned method. The cervices were stretched in growing steps and 
allowed to relax for 5 min. After every 5 min, the next initial tension was set, in 1-g steps 
between 1 and 12 g. In the evaluation of cervical resistance, the initial tension of the cervix 
was plotted versus the stretch after 5 min. Straight lines were suited by linear regression and 
the slopes of the lines were applied to express the degree of resistance. A steeper slope 
reflected a higher resistance. 
Measurement of COX activity 
The COX activity was measured in 22-day-pregnant and non-pregnant myometrial, tracheal, 
cervical and non-pregnant tracheal samples (n=6/group). After the preparation, the smooth 
muscle tissues were incubated in organ bath as described above.  Then, they were perfused 
with cold Tris buffer pH 7.4 to clear away any red blood cells and clots, frozen in liquid 
nitrogen and stored at −80 °C until the measurement.  On the day of assay, samples were 
homogenized cold buffer (0.1 M Tris-HCl, pH 7.8, containing 1 mM EDTA), centrifuged at 
10.000 ×g for 15 min at 4 °C. The supernatant was stored on ice. The activity of COX 
enzymes was determined by COX Activity Assay Kit (Cayman Chemicals, Ann Arbor, MI) 
which measures the peroxidase activity of COX. The peroxidase activity is assayed with the 
colorimetric method by monitoring the appearance of oxidized N,N,N′,N′-tetramethyl-p-
phenylenediamine (TMPD) at 590 nm. 
In vivo studies 
The pregnant rats were split into four groups (n=8/group): (1) control, (2) tocopherol treated, 
(3) rofecoxib-treated, (4) tocopherol+rofecoxib-treated. The animals received a single 
treatment with 1 ml water (control), 250 mg/kg tocopherol, 5 mg/kg rofecoxib or 250 mg/kg 
tocopherol+5 mg/kg rofecoxib on the 21 day of pregnancy at 16:00 h by oral gavage. After 
the treatment, the onset of deliveries was detected and the elapsed hours were registered. 
Presence of blood or first foetus in the bedding was regarded as the onset of labour.  
Statistical analyses 
To the data were analysed by using Prism 5.01 (GraphPad Software, USA) computer program 
while the values were evaluated statistically with unpaired t-test and ANOVA Tukey-Multiple 
Comparison Test. 
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Results 
Results of in vitro studies 
The KCl-evoked contraction of 22-day-pregnant uteri was higher than in non-pregnant uteri. 
In presence of tocopherol (10-7 M) the contraction of non-pregnant did not change while that 
of pregnant was increased significantly. (Fig. 1.) 
 
 
 
 
 
 
 
 
 
The non-selective COX inhibitor diclofenac (10−9–10−5 M) (Fig. 2/a) and the selective COX-2 
inhibitor rofecoxib (10−10–10−5 M) (Fig. 2/b) inhibited the contractions of non-pregnant uterus 
in a concentration-dependent manner. After tocopherol (10-7 M) treatment, the relaxant effects 
of diclofenac and rofecoxib remained unchanged. 
  
  
a b 
Fig. 1: Alteration of the uterine contractions (expressed in area under the curve - AUC) on non-
pregnant (empty columns) and 22-day-pregnant (striped columns) uteri by incubation with 
tocopherol. (ns > 0.05; *** p < 0.001) 
Fig. 2: The relaxant effect of non-selective COX inhibitor diclofenac (a) and selective COX-2 
inhibitor rofecoxib (b) on non-pregnant rat uteri alone and in the presence of tocopherol. 
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In the 22-day-pregnant uteri tissues, the maximum relaxant effect of selective COX-2 
inhibitor rofecoxib (Fig. 3/b) was 55.33 %; it was 3.5 times as higher as than that of 
diclofenac (Fig. 3/a); (15.29 %). With tocopherol the impact of both compounds was 
enhanced significantly in each concentration. 
 
 
 
 
 
 
 
 
When COX-2 was inhibited with one dose of rofecoxib (10-7 M) before the administration of 
diclofenac (10−9–10−5 M), then the relaxant effect of diclofenac was practically ceased. 
(continuous line) The presence of tocopherol did not change this action. (dotted line) (Fig. 
4) 
 
  
a b 
Fig. 3: The relaxant  effect of nonselective COXi diclofenac (a) and selective COX-2 inhibitor 
rofecoxib (b) on 22-day-pregnant rat uteri alone and in the presence of tocopherol (10-7 M).  
 (* p < 0.05; ** p < 0.01; *** p < 0.001) 
Fig. 4: The concentration-response curves of diclofenac after COX-2 inhibition with rofecoxib alone 
(continuous line) and in the presence of tocopherol (dotted line). 
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When COX-1 was inhibited with selective COX-1 inhibitor SC-560 (10-7 M) (continuous 
line), the relaxing effect of rofecoxib was enhanced as compared with Fig. 8/B 
(concentration-response curve of rofecoxib).  The tocopherol significantly increased further 
the uterine relaxant action of rofecoxib. (dotted line) (Fig. 5) 
 
 
Both diclofenac (10−9–10−5 M) (Fig. 6/a) and rofecoxib (10−10–10−5M) (Fig. 6/b) decreased 
the tone of tracheal samples. Diclofenac and rofecoxib reduced the average tone by 46.8 ± 5.0 
mg and 32.6 ± 10.4 mg, respectively. Tocopherol impacted the effect of diclofenac and 
rofecoxib only in lower concentrations 
 
  
a b 
Fig. 5: The concentration-response curves of rofecoxib after COX-1 inhibition with SC-560 alone 
(continuous line) in the presence of tocopherol (dotted line). (ns > 0.05; * p < 0.05; ** p < 0.01; 
*** p < 0.001) 
Fig. 6: Tone-reducing effect of non-selective COXi diclofenac (a) and selective COX-2 inhibitor 
rofecoxib (b) on trachea tissues. (ns > 0.05; * p < 0.05) 
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Neither the investigated COX inhibitors and tocopherol alone nor COX inhibitors combined 
tocopherol altered the cervical resistance in non-pregnant cervical samples. (Fig. 7) 
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In the 22-day-pregnant samples, the control cervical resistance was 0.85 ± 0.01. Alone the α-
tocopherol, selective COXi diclofenac and selective COXi rofecoxib reduced the resistance. 
The selective COX-1 inhibitor SC-560 possessed no effect on cervical resistance. On the 
other hand, α-tocopherol combined with COX inhibitors, decreased further the resistance in 
all cases. (Fig. 8) 
 
  
Fig. 7: Alteration of non-pregnant cervical resistance by tocopherol, different selectivity COX inhibitors 
alone and combined with tocopherol. 
Fig. 8: Alteration of 22-day-pregnant cervical resistance by tocopherol, different selectivity COX 
inhibitors alone and combined with tocopherol. (ns > 0.05; # p < 0.05; ***/### p < 0.001) 
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The highest level of total COX activity was found in trachea tissues, while the lowest was in 
non-pregnant uteri. After pre-treatment with tocopherol, neither the COX activity of the 
trachea nor the COX activity of non-pregnant uteri and cervix changed. In 22-day-pregnant 
uterus and cervix, the total COXs activities were significantly increased by pre-treatment with 
tocopherol. The activity of COX-1 was not altered in the samples in the presence of 
tocopherol. However, the activity of COX-2 was enhanced significantly in tocopherol pre-
treated 22-day-pregnant uterus and cervix. (Fig. 9) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
a 
b c 
Fig. 9: Changes in the COXs activities in control and tocopherol treated tissues. (a): total COXs activity, 
(b): COX-1 activity, (c): COX-2 activity (np: non-pregnant, p: 22-day-pregnant); (ns > 0.05; * p < 0.05; 
** p <0.01; ***p < 0.001) 
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Results of in vivo studies 
The delivery occurred 40 hours after the water treatment in control rats. Neither tocopherol- 
nor rofecoxib-treatment was able to change the time of delivery as compared with control 
groups. However, in case of co-administration of tocopherol and rofecoxib, the labour had 
been initiated 16 hours earlier as compared with the control group. (Fig. 10) 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
The whole reproductive tract undergoes a drastic transformation during pregnancy which is 
regulated by difficult biological mechanisms; this action is still not widely understood. PGs 
play an important role in uteri contractions, relaxations and also in cervical ripening at the end 
of pregnancy. 
During pregnancy, the cervix goes through the ripening process which is induced by 
numerous endogenous substances such as PGs. The pregnant cervix become dilated and 
softened, especially near term, thus the resistance of non-pregnant cervix is stronger than that 
of pregnant cervical resistance. This phenomenon was clearly confirmed in our study. We 
presumed that COX inhibitors would enhance cervical resistance through abating the levels of 
PGs. Surprisingly, COX-1 selective inhibitor SC-560 possessed no action on cervical 
resistance, while the non-selective inhibitor diclofenac and COX-2 selective inhibitor 
rofecoxib lowered the pregnant cervical resistance.  
Fig. 10: Changes the initiation time of delivery by tocopherol, rofecoxib and tocopherol combined 
with rofecoxib. (ns > 0.05; ***p < 0.001) 
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Over the past 60 years, the cervix has been known as a particularly collagenous structure. 
Researchers have underrated the existence of smooth muscle in the cervix believed that 
(cervical smooth muscle) CSM stays inactive in pregnancy and labour, and interpreted the 
premature cervical failure by the disorder of the cervical collagen network. The CSM function 
has received more attention in the last years, it stayed active during pregnancy and labour in 
addition, it may contributed efficiently to cervical remodelling in rats. Moreover, it has a 
possible role in uterine contraction. At the end of cervical ripening, collagens are degraded by 
matrix metalloproteinase, while the content of CSM remains fixed. Hence, it is possible that 
CSM may influence all phases of cervical remodelling and it might have a key function in the 
dilatation phase as well. Our isolated organ bath experiments were carried out on pregnancy 
day 22. Since anticipated delivery of SD rats occurs on 22nd day of pregnancy, the cervical 
samples had probably undergone the ripening process. Based on these facts, we presumed that 
the differences in the selectivity of COX inhibitors imply that COXs may affect the dilatation 
of CSM.  
According to our results, pre-treatment with tocopherol unambiguously raised the area under 
the curve of KCl-evoked contractions in pregnant uteri. This implies that tocopherol may 
enhance the contractibility of pregnant myometrium. These results suggest that pre-treatment 
with tocopherol may increase the contractility of uteri by enhancing the activity of COX-2 
enzyme, and hereby the relaxant effect of COX inhibitors may be more pronounced, 
especially in the case of selective COX-2 inhibitors. To confirm this hypothesis, the alteration 
of the activity of COXs was measured in the tissues before and after the incubation with 
tocopherol. Tocopherol itself induced the COX activity and shifted the COX-1 and COX-2 
ratio to COX-2 in pregnant uteri. When COX-1 was blocked by selective inhibitor SC-560, 
the relaxant effect of rofecoxib increased alone and further increased in the presence of 
tocopherol. However, when COX-2 was inhibited by the selective blocker rofecoxib, the 
dose-response curve of diclofenac was shifted slightly left, and after pre-treatment with 
tocopherol the significant difference between the curves practically ceased. These findings 
provide further evidence that COX-2 is predominant in pregnant uterine contraction and the 
tocopherol-induced modification of the COX-1 and COX-2 ratio led to the increased relaxing 
efficacy of COX inhibitors. In cervical samples, we found that tocopherol can reduce the 
pregnant cervical resistance and enhance the resistance-inhibition effect of diclofenac and 
rofecoxib. Its effect was maintained in the presence of COX-1 selective inhibitor SC-560. 
These results can be explained by COX activity measurements in which alpha-tocopherol 
decreased the activity of COX-2 in pregnant cervical samples. These findings suggest that 
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COX-2 mediated PG liberation may have a crucial role in the contraction of CSM during 
delivery. Moreover, tocopherol may have a synergist effect with COX inhibitors on rat 
cervical resistance. 
The in vivo experiments implied that tocopherol together with COX-2 selective rofecoxib 
were able to shorten the gestational period by 16 hours. In the in vitro experiments we 
determined that they have a synergist effect on the reduction of cervical resistance. On the 
other hand, the co-administration of these compounds significantly reduced the myometrium 
contractions that would predict a delay in delivery. Thus, this in vivo result suggests that the 
joint effect of tocopherol and rofecoxib on the reduction of cervical resistance is predominant 
over their myometrium relaxing effect.  
Finally, in trachea tissues the levels of COX-1 and COX-2 activity were similar which 
correlates with the previous findings in literature. Diclofenac decreased the tracheal tone more 
than rofecoxib, suggesting that COX-1 derived prostaglandins may play a larger role in 
airway smooth muscle contraction in rat. Interestingly, pre-treatment with tocopherol 
increased the relaxing effects of rofecoxib and diclofenac, but only in low concentrations of 
the drugs. We have no clear explanation for this phenomenon, but it might be related to the 
weak antioxidant capacity of rat trachea as compared with pregnant uterus. 
Conclusion 
In the light of our results, we can conclude that α-tocopherol has a tissue specific COX 
activity modifying action thus, it can influence the effect of COX inhibitors. In pregnant uteri 
tocopherol can strengthen COX-2 activity, leading to the stronger relaxant effect of COX-2 
inhibitor. On the other hand, α-tocopherol potentiates the cervical-resistance reducing effect 
of COX inhibitors via the inhibition of COX-2 activity in late-term and ripened rat cervix. 
Interestingly, alpha-tocopherol has an opposite effect on COX-2 activity in pregnant cervices 
as compared with pregnant myometria. Finally, the single oral administration with tocopherol 
and rofecoxib can shorten the gestational period and accelerate the onset of labour. This result 
suggests that this synergist effect between tocopherol and rofecoxib on the reduction of 
cervical resistance is prevailing over their myometrium relaxing effect.  
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